Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Stock analysts at Desjardins lowered their Q4 2024 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a report issued on Monday, November 11th. Desjardins analyst A. Leon now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their prior estimate of $0.01. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s FY2025 earnings at ($0.06) EPS and FY2026 earnings at ($0.14) EPS.
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The company had revenue of C$3.52 million during the quarter.
Inovalis Real Estate Investment Trust Stock Performance
About Inovalis Real Estate Investment Trust
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Articles
- Five stocks we like better than Inovalis Real Estate Investment Trust
- The 3 Best Fintech Stocks to Buy Now
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Tariff Troubles: 3 Stocks Planning Higher Prices
- 3 Small Caps With Big Return Potential
- Mercer Near Rock Bottom: Is This High-Yield Play Set to Soar?
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.